CClinicalTrials.gg
Not yet recruitingNCT06570343Updated Oct 1, 2024

Analgesic Efficacy of Intrathecal Fentanyl-Morphine Combination Versus Morphine Alone for Intraoperative Pain During Elective Cesarean Delivery

A Phase 4 interventional study of Fentanyl-Morphine and Morphine in Intraoperative Pain, sponsored by Seoul National University Hospital. Not yet recruiting. Open to female participants aged 19 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year ago, but the record still lists the study as not yet recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
19 Years to 99 Years
Sex
Female
01

Study summary

Pregnant women scheduled for elective cesarean sections under spinal anesthesia are randomly assigned to two groups: 1) the Fentanyl-Morphine (FM) group, and 2) the Morphine (M) group. In addition to 11.5 mg of bupivacaine, the FM group receives 15 μg of fentanyl and 50 μg of morphine intrathecally, while the M group receives 50 μg of morphine intrathecally. The incidence of intraoperative pain with a Numerical Rating Scale (NRS) score of 4 or higher is compared between the two groups to evaluate the analgesic effects of combined intrathecal fentanyl-morphine therapy versus morphine alone.

02

Conditions studied

  • Intraoperative Pain
03

In context

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Parturients of gestational age > 37 weeks, scheduled for cesarean section under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Contraindication to spinal anesthesia
  • Any sign of onset of labor
  • Emergency cesarean section
  • Body weight \< 40 kg or > 120 kg
  • Height \< 140 cm or > 190 cm
  • Severe underlying cardiovascular disease
  • Known fetal anomaly
  • Preeclampsia
  • History of hypersensitivity to fentanyl or morphine
  • Chronic opioid use
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
186 participants (estimated)

Study arms

  • Experimental
    Fentanyl-Morphine

    Spinal anesthesia with heavy bupivacaine, fentanyl and morphine

    Drug: Fentanyl-Morphine

  • Active comparator
    Morphine

    Spinal anesthesia with heavy bupivacaine and morphine

    Drug: Morphine

Interventions

  • DrugFentanyl-Morphine

    Intrathecal injection of bupivacaine, fentanyl and morphine

  • DrugMorphine

    Intrathecal injection of bupivacaine and morphine

06

What researchers measure

Primary outcomes

  1. Incidence of intraoperative pain

    Incidence of intraoperative pain of NRS (numeric rating scale) score of 4 or higher

    Time frame: From first skin incision to end of surgery

Secondary outcomes

  1. Time of occurence of intraoperative pain

    Time of occurence of intraoperative pain of NRS (numeric rating scale) score of 4 or higher

    Time frame: From first skin incision to end of surgery

  2. Incidence of intraoperative rescue analgesic administration

    Incidence of intraoperative rescue analgesic administration

    Time frame: From first skin incision to end of surgery

  3. Total amount of intraoperative opioid rescue analgesic administration

    Total amount of intraoperative opioid rescue analgesic administration (morphine mg equivalent)

    Time frame: From first skin incision to end of surgery

  4. Total amount of intraoperative non-opioid rescue analgesic administration

    Total amount of intraoperative non-opioid rescue analgesic administration (mg)

    Time frame: From first skin incision to end of surgery

  5. Intraoperative pain characteristics

    Intraoperative pain characteristics

    Time frame: From first skin incision to end of surgery

  6. Conversion to general anesthesia

    Conversion to general anesthesia

    Time frame: From first skin incision to end of surgery

  7. Preoperative anxiety

    Preoperative anxiety (APAIS, Amsterdam Preoperative Anxiety and Information Score)

    Time frame: On the day before surgery

  8. Preoperative anxiety

    Preoperative anxiety (APAIS, Amsterdam Preoperative Anxiety and Information Score)

    Time frame: On the day of surgery

  9. Total amount of postoperative opioid analgesic administered

    Total amount of postoperative opioid analgesic administered (morphine mg equivalent)

    Time frame: From end of surgery to 24 hours after end of surgery

  10. Incidence of intraoperative nausea/vomiting

    Incidence of intraoperative nausea/vomiting

    Time frame: From induction to end of surgery

  11. Incidence of postoperative nausea/vomiting

    Incidence of postoperative nausea/vomiting

    Time frame: From end of surgery to 24h post-surgery

  12. Incidence of intraoperative shivering

    Incidence of intraoperative shivering

    Time frame: From induction to end of surgery

  13. Incidence of intraoperative hypotension

    Incidence of intraoperative hypotension (MBP\<65 mmHg)

    Time frame: From induction to end of surgery

  14. Incidence of intraoperative pruritus

    Incidence of intraoperative pruritus

    Time frame: From induction to end of surgery

  15. Incidence of postoperative pruritus

    Incidence of postoperative pruritus

    Time frame: From end of surgery to 24h post-surgery

  16. Immediate post-operative patient satisfaction

    Immediate post-operative patient satisfaction on intraoperative analgesia

    Time frame: At the end of surgery

  17. Obstetric Quality of Recovery-11K score

    Obstetric Quality of Recovery-11K score

    Time frame: At 24 hours post-surgery

  18. Time of first postoperative pain

    Time of first postoperative pain

    Time frame: From end of surgery to 24 hours post-surgery

  19. Pain score at 8 hours post-surgery

    Pain score at 8 hours post-surgery (NRS, numeric rating scale pain score, 0: no pain; 10: worst imaginable pain)

    Time frame: at 8 hours post-surgery

  20. Pain score at 16 hours post-surgery

    Pain score at 16 hours post-surgery (NRS, numeric rating scale pain score, 0: no pain; 10: worst imaginable pain)

    Time frame: at 16 hours post-surgery

  21. Pain score at 24 hours post-surgery

    Pain score at 24 hours post-surgery (NRS, numeric rating scale pain score, 0: no pain; 10: worst imaginable pain)

    Time frame: at 24 hours post-surgery

  22. Pain score at 2 hours post-surgery

    Pain score at 2 hours post-surgery (NRS, numeric rating scale pain score, 0: no pain; 10: worst imaginable pain)

    Time frame: at 2 hours post-surgery

  23. Incidence of postoperative hypotension

    Incidence of postoperative hypotension (MBP\&lt;65 mmHg)

    Time frame: From end of surgery to 24 hours post-surgery

  24. Incidence of postoperative shivering

    Incidence of postoperative shivering

    Time frame: From end of surgery to 24 hours post-surgery

  25. 24-hour post-operative patient satisfaction

    24-hour post-operative patient satisfaction on postoperative analgesia

    Time frame: at 24 hours post-surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570343
Lead sponsor
Seoul National University Hospital
Responsible party
Jin-Tae Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Aug 26, 2024
Start date
Sep 20, 2024 (estimated)
Primary completion
Sep 20, 2025 (estimated)
Completion
Dec 25, 2025 (estimated)
Last update
Oct 1, 2024

Study contacts

Jin-Tae Kim, M.D., Ph.D
Contact
jintae73@gmail.com
+82-2-2072-2467

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion